+86-400-890-9989
Product Catalog
> PAI-1 / SerpinE1 Protein & Antibody PAI-1 / SerpinE1 Protein & Antibody
Plasminogen Activator Inhibitor 1 / Serpin peptidase inhibitor, clade E, member 1
PAI-1 / SerpinE1 Products
PAI-1 / SerpinE1 Protein, Recombinant
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat No |
| PAI-1/SerpinE1 | Human | PAI-1/SerpinE1 Protein, Recombinant | 10296-H08H |
PAI-1 / SerpinE1 Antibody
| Molecule | Application | Description //For Detailed Info. and Price------CLICK! | Cat No |
| Human PAI-1/SerpinE1 |
WB, ELISA | PAI-1/SerpinE1 Antibody, Rabbit PAb | 10296-RP01 |
| Human PAI-1/SerpinE1 |
WB, ELISA | PAI-1/SerpinE1 Antibody, Rabbit PAb (Antigen Affinity Purified) | 10296-RP02 |
PAI-1 / SerpinE1 cDNA Clone
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat No |
| PAI-1/SerpinE1 | Human | Homo sapiens PAI-1/SerpinE1 cDNA Clone | HG10296-M |
PAI-1 / SerpinE1 Related Areas
Cancer>>Cancer Biomarkers>>PAI-1/SerpinE1
Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>Serpin Superfamily>>PAI-1/SerpinE1
Immunology>>Innate Immunity>>Coagulation>>PAI-1/SerpinE1
Cardiovascular>>Coagulation>>PAI-1/SerpinE1
PAI-1 / SerpinE1 Alternative Names
PAI-1, SERPINE1, PAI1, PAI, PLANH1, serpin E1 [Homo sapiens]
PAI-1, Serpine1, PAI1, PAI, Planh1 serpin E1 [Mus musculus]
PAI-1 / SerpinE1 Related Products
Protein Products
Antibody Products
cDNA Clone Products
PAI-1 / SerpinE1 Background
Plasminogen activator inhibitor 1, also known as PAI-1, Endothelial plasminogen activator inhibitor, SerpinE1 and PLANH1, is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Defects in SerpinE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma. High concentrations of SerpinE1 have been associated with thrombophilia which is an autosomal dominant disorder in which affected individuals are prone to develop serious spontaneous thrombosis. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling. PAI-1, in its active state, also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family. The mechanisms of PAI-1 overexpression during obesity are complex, and it is conceivable that several inducers are involved at the same time at several sites of synthesis. PAI-1 is also implicated in adipose tissue development and in the control of insulin signaling in adipocytes. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis and insulin resistance.
PAI-1 / SerpinE1 Related Studies
- Alessi MC, et al. (2006) PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 26(10): 2200-7.
- Schneider DJ, et al. (2008) The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost. 100(6): 1037-40.
- Dupont DM, et al. (2009) Biochemical properties of plasminogen activator inhibitor-1. Front Biosci. 14: 1337-61.
